Novocure Ltd (NVCR) Stake Raised by Teachers Advisors LLC

Teachers Advisors LLC grew its position in shares of Novocure Ltd (NASDAQ:NVCR) by 1.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 142,965 shares of the medical equipment provider’s stock after buying an additional 2,712 shares during the quarter. Teachers Advisors LLC owned 0.15% of Novocure worth $7,491,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of NVCR. FMR LLC grew its holdings in shares of Novocure by 37.9% during the third quarter. FMR LLC now owns 10,845,246 shares of the medical equipment provider’s stock valued at $568,292,000 after buying an additional 2,983,125 shares during the last quarter. BlackRock Inc. boosted its holdings in Novocure by 22.4% in the second quarter. BlackRock Inc. now owns 4,620,546 shares of the medical equipment provider’s stock worth $144,623,000 after purchasing an additional 846,277 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in Novocure by 89.0% in the third quarter. Macquarie Group Ltd. now owns 1,104,117 shares of the medical equipment provider’s stock worth $57,856,000 after purchasing an additional 519,988 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Novocure by 276.3% in the second quarter. Renaissance Technologies LLC now owns 682,603 shares of the medical equipment provider’s stock worth $21,365,000 after purchasing an additional 501,203 shares during the last quarter. Finally, Credit Suisse AG boosted its holdings in Novocure by 87.2% in the third quarter. Credit Suisse AG now owns 945,654 shares of the medical equipment provider’s stock worth $49,552,000 after purchasing an additional 440,543 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Several brokerages recently issued reports on NVCR. Deutsche Bank set a $44.00 target price on shares of Novocure and gave the stock a “hold” rating in a report on Thursday, September 20th. Zacks Investment Research cut shares of Novocure from a “hold” rating to a “sell” rating in a report on Thursday, September 27th. Wells Fargo & Co raised their target price on shares of Novocure from $53.00 to $58.00 and gave the stock a “positive” rating in a report on Wednesday, September 19th. JPMorgan Chase & Co. restated a “buy” rating on shares of Novocure in a report on Sunday, September 16th. Finally, Mizuho restated a “buy” rating and issued a $58.00 target price on shares of Novocure in a report on Friday, October 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $48.00.

In other news, insider Pritesh Shah sold 38,781 shares of Novocure stock in a transaction on Wednesday, December 12th. The shares were sold at an average price of $36.00, for a total transaction of $1,396,116.00. Following the transaction, the insider now owns 39,619 shares in the company, valued at approximately $1,426,284. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gabriel Leung sold 5,000 shares of Novocure stock in a transaction on Monday, December 10th. The stock was sold at an average price of $33.49, for a total transaction of $167,450.00. Following the transaction, the director now owns 65,000 shares in the company, valued at approximately $2,176,850. The disclosure for this sale can be found here. Insiders sold 187,769 shares of company stock worth $7,325,336 in the last 90 days. 15.30% of the stock is currently owned by corporate insiders.

Shares of NVCR stock opened at $43.25 on Monday. Novocure Ltd has a 12-month low of $19.06 and a 12-month high of $53.70. The company has a debt-to-equity ratio of 1.30, a quick ratio of 5.72 and a current ratio of 6.17. The company has a market capitalization of $3.76 billion, a P/E ratio of -61.79 and a beta of 2.86.

Novocure (NASDAQ:NVCR) last issued its earnings results on Thursday, October 25th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Novocure had a negative net margin of 25.37% and a negative return on equity of 52.72%. The company had revenue of $64.76 million for the quarter, compared to analysts’ expectations of $65.61 million. As a group, equities analysts predict that Novocure Ltd will post -0.68 EPS for the current year.

WARNING: This story was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/01/14/novocure-ltd-nvcr-stake-raised-by-teachers-advisors-llc.html.

About Novocure

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.

Featured Story: How dollar cost averaging works

Institutional Ownership by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply